Fig. 3.
Treatment preference at Month 12 for participants receiving CAB+RPV LA Q2M.
Figure 3 was presented previously at IDWeek; October 21–25, 2020; Virtual; Oral. CAB, cabotegravir; LA, long-acting; Q2M, every 2 months; RPV, rilpivirine.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.